Bortezomib-Induced Sensorineural Hearing Loss May Be Reversible with Intratympanic Dexamethasone
<b>Background</b>: Bortezomib, a proteasome inhibitor used in multiple myeloma (MM), is associated with several adverse effects, most notably peripheral neuropathy. Ototoxicity, however, remains a rare and underrecognized complication. <b>Case presentation</b>: We report the case of a 74-year-old ma...
Furkejuvvon:
| Váldodahkkit: | , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
MDPI AG
2026-01-01
|
| Ráidu: | Hematology Reports |
| Fáttát: | |
| Liŋkkat: | https://www.mdpi.com/2038-8330/18/1/9 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|